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BACKGROUND: Deregulation of fibroblast growth factor receptor 3 (FGFR3) is involved in several malignancies. Its role in colorectal
cancer has not been assessed before.
METHODS: Expression of FGFR3 in human colorectal tumour specimens was analysed using splice variant-specific real-time reverse
transcriptase PCR assays. To analyse the impact of FGFR3-IIIc expression on tumour cell biology, colon cancer cell models
overexpressing wild-type (WT-3b and WT3c) or dominant-negative FGFR3 variants (KD3c and KD3b) were generated by either
plasmid transfection or adenoviral transduction.
RESULTS: Although FGFR3 mRNA expression is downregulated in colorectal cancer, alterations mainly affected the FGFR3-IIIb splice
variant, resulting in an increased IIIc/IIIb ratio predominantly in a subgroup of advanced tumours. Overexpression of WT3c increased
proliferation, survival and colony formation in all colon cancer cell models tested, whereas WT3b had little activity. In addition, it
conferred sensitivity to autocrine FGF18-mediated growth and migration signals in SW480 cells with low endogenous FGFR3-IIIc
expression. Disruption of FGFR3-IIIc-dependent signalling by dominant-negative FGFR3-IIIc or small interfering RNA-mediated
FGFR3-IIIc knockdown resulted in inhibition of cell growth and induction of apoptosis, which could not be observed when FGFR3-IIIb
was blocked. In addition, KD3c expression blocked colony formation and migration and distinctly attenuated tumour growth in SCID
mouse xenograft models.
CONCLUSION: Our data show that FGFR3-IIIc exerts oncogenic functions by mediating FGF18 effects in colorectal cancer and may
constitute a promising new target for therapeutic interventions.
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Pathogenesis of cancer results from progressive deregulation of
cell homeostasis. It affects proliferation and cell death, differentia-
tion, cell migration and tissue interactions (Hanahan et al, 1996)
by deregulating intracellular signalling pathways. Such deregula-
tion frequently involves receptor tyrosine kinases – a fact that
makes those receptors suitable targets for cancer therapy (Zwick
et al, 2001). Fibroblast growth factors (FGFs) and their tyrosine
kinase receptors (FGFR) have significant roles in development,
wound healing and angiogenesis. Consequently, their deregulation
can contribute to tumour development at several levels by
stimulating proliferation, survival, cell migration and vascularisa-
tion of tumours (Eswarakumar et al, 2005).
The human genome contains 22 genes coding for FGFs and four
genes coding for functional FGFRs. The receptors in general
possess an extracellular ligand-binding domain consisting of three
immunoglobulin (Ig)-like loops, a short transmembrane domain
and an intracellular kinase domain. Differential splicing creates
multiple variants lacking IgG loops, the transmembrane domain or
the cytoplasmic domain (Powers et al, 2000). Ligand binding
occurs in Ig-like loop III, in which alternative splice variants result
in IIIb and IIIc isoforms of FGFR1–3, with different ligand
specificities (Powers et al, 2000; Ornitz and Itoh, 2001). IIIb forms
are frequently expressed in epithelial tissues, whereas IIIc forms
are observed mainly in the mesenchyme (Orr-Urtreger et al, 1993;
Murgue et al, 1994; Scotet and Houssaint, 1995), where they
mediate tissue interactions in normal development and wound
healing, together with ligands expressed in adjacent tissues.
Carcinomas have been observed to switch expression of FGFR to
the mesenchymal isoform, enabling cells to receive signals usually
restricted to the connective tissue, leading to more aggressive
phenotypes (Yan et al, 1993; Carstens et al, 1997).
Fibroblast growth factor receptor 3 (FGFR3) has been described
as a negative regulator of bone growth (L’Hote and Knowles, 2005)
and is also involved in carcinogenesis. Epithelial cells of the
pancreas, kidney or lung express the splice-variant FGFR3-IIIb,
whereas splice-variant IIIc has been found, for example, in
chondrocytes (Murgue et al, 1994; Scotet and Houssaint, 1995;
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sWuechner et al, 1996; L’Hote and Knowles, 2005). In the intestinal
epithelium of mice, both splice variants of FGFR3 are expressed in
undifferentiated crypt cells, suggesting a role of FGFR3-IIIc in cell
proliferation (Vidrich et al, 2004). In healthy epithelium, FGFR3
expression is regulated by FGF7 and transforming growth factor b,
which are mediators of mucosal healing (Kanai et al, 1997a,b).
In malignant cells, FGFR3 can be deregulated by three different
mechanisms: activating mutations, differential expression and
alterations in the predominant splice variant. Activating mutations
in FGFR3 have been observed both in the ligand-binding and
kinase domains in multiple myelomas, as well as in cancers of the
bladder and cervix (L’Hote and Knowles, 2005). They are, however,
rare in colorectal tumours (Jang et al, 2000). Here, downregulation
of FGFR3 expression by a mechanism involving FGFR1 and
differential splicing has been observed (Jang et al, 2000; Jang,
2005). No information is available yet with regard to the role of the
IIIc splice variant of FGFR3 in colorectal tumours. This receptor
may have a major impact on tumour cell characteristics because of
its broad ligand spectrum (FGFs 1, 2, 4, 6, 9 and 18) compared with
FGFR3-IIIb (FGFs 1 and 9 exclusively) (Kanai et al, 1997a).
Consequently, a switch to IIIc as the main FGFR3 isoform may
permit stimulation of tumour cells by those additional factors
(Pandit et al, 2002; Davidson et al, 2005).
Among the FGFR3 ligands, FGF18 is upregulated in colon
tumourigenesis (Shimokawa et al, 2003), allowing autocrine
growth stimulation through FGFR3-IIIc. Accordingly, we have
recently demonstrated strong autocrine effects of FGF18 on
tumour cell growth and survival (Sonvilla et al, 2008). To
investigate the role of FGFR3-IIIc in the pathogenesis of colorectal
tumours, we have analysed expression of IIIb and IIIc variants in
colorectal tumour tissue and examined the impact of FGFR3-IIIc
signalling on growth, survival and migration of colorectal tumour
cells in vitro and in vivo.
MATERIALS AND METHODS
Tissue specimen
Tissue specimens of colorectal carcinoma and normal mucosa
were obtained from patients undergoing surgery for colorectal
cancer after obtaining informed consent from all patients.
Immediately after surgery, tissue specimens were frozen in liquid
N2 until extraction of RNA. The tissue specimen has a tumour cell
content of at least 70%, as judged from the histology of
immediately adjacent tissue. The study had previous approval of
the ethics committee of the Municipal Hospitals of Vienna.
Cell lines
SW480, Caco2 and HCT116 colon carcinoma cell lines were
obtained from the American Type Culture Collection. The cell lines
were kept under standard tissue culture conditions using Minimal
Essential Medium containing 10% foetal calf serum (FCS). The
Vaco235 colon adenoma cell line was a gift from JKV Willson
(Ireland Cancer Centre, Case Western University, Cleveland, OH,
USA) and was maintained as described in the study by Willson
et al (1987). LT97 adenoma cells were maintained as described by
Richter et al, (2002). AKH14 and H64 colon carcinoma cell lines
were established at our institute from a liver and brain metastasis,
respectively, and cultivated in RPMI with 10% FCS.
Isolation of RNA and cDNA synthesis
Total RNA was isolated from subconfluent cultures or frozen colon
tissue specimens using Trifast reagent according to the manufac-
turer’s instructions (PeqLab, Erlangen, Germany). First-strand
cDNA was synthesised using RevertAid mouse Moloney leukemia
virus (MMuLV) reverse transcriptase (Fermentas, Burlington,
Ontario, Canada) and random hexamer primers (GE Healthcare,
Piscataway, NJ, USA).
Quantitative RT–PCR analysis
Taqman assays from Applied Biosystems (Foster City, CA, USA)
were used to determine expression of total FGFR3 (Hs00179829),
FGFR3-IIIc (Hs00997397-m1) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Hs 99999905-m1) mRNAs using quan-
titative reverse transcriptase PCR (RT–PCR). Probes specific
for FGFR3-IIIb were custom designed by Applied Biosystems to
recognise the exon 6/7 boundary specific for IIIb splice variants.
Reactions were carried out on an ABI PRISM 7000 system (Applied
Biosystems) using standard Taqman assay conditions. The FGFR3
gene expression in the cells and tumours was calculated as x-fold
change compared with the corresponding normal mucosa using
GAPDH as the control gene for normalisation using a standard
curve method. In addition, selected RT–PCR experiments were
performed using cycles of 40s denaturation at 941C, 40s annealing
at 561C and 40s extension at 721C. Amplifications were carried out
for 40 and 23 cycles in case of FGFR and GAPDH, respectively.
PCR products were separated on 6% acrylamide gels. Bands were
stained with ethidium bromide and quantified using a GelDoc
system (Biorad, Hercules, CA, USA) and Image Quant 5.0 (GE
Healthcare) software.
Overexpression of FGFR in colon carcinoma cells
Stable transfectants of SW480 and HCT116 cells were prepared
with plasmids expressing wild-type FGFR3-IIIc (WT3c) or kinase-
dead FGFR3-IIIc (KD3c, mutation K508R) driven by a CMV
promoter (plasmids kindly provided by DJ Donoghue; University
of California, San Diego, CA, USA). The wild-type and kinase-dead
FGFR3-IIIb constructs (WT3b, KD3b) were constructed by
removing the exon 8 sequence in the respective FGFRIII-3c vectors
and substituting it with exon 7. For that purpose, the respective
sequence was amplified with primers forward 50-CTGCGTC
GTGGAGAACAAG-30 and reverse 50-CCGAGACAGCTCCCATT
TG-30 and Pfu proofreading polymerase (Stratagene, La Jolla, CA,
USA) from cDNA of Vaco235 cells, which predominantly express
the IIIb form. The PCR product was digested with Eco47III and
XhoI, and ligated into the similarly digested KD3c plasmid. The
resulting KD3b plasmid was checked by sequencing. Cells that
overexpressed FGFR3 were produced through transfection by
electroporation. Controls received equal amounts of vector DNA
(pcDNA3, Invitrogen, Lofer, Austria). Stably overexpressing cells
were obtained by selection with 0.6mgml
–1geneticin (G418; PAA,
Pasching, Austria).
The dominant-negative FGFR3-IIIc adenoviral construct KD3-
IIIcv was prepared using the KD3c plasmid and the AdEasy
adenoviral system (Stratagene), following the manufacturer’s
instructions. As controls, adenoviral constructs expressing GFP
(GFPv) or a scrambled sequence (control virus, Cv) were used, all
controlled by a CMV promoter. Cells were seeded at a density of
2 10
5 in six-well plates in medium containing 10% FCS.
Subsequently, they were infected at a multiplicity of infection of
1 for SW480 cells and 20 for Caco2 cells, yielding 490% of green
fluorescent cells with the GFP virus.
Knockdown of gene expression
Small interfering RNAs (siRNAs) specifically targeting the IIIc-
specific exon 8 or the IIIb-specific exon 7, but not the respective
other exon, were custom designed by Ambion (Applied Biosys-
tems). Cells were seeded at a density of 2 10
5 cells per well into
six-well plates in medium containing 10% serum. After 24h, they
were transfected with 3ml Silentfect (BioRad) and 20pmol of
siRNA per well in culture medium without serum. A scrambled
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ssiRNA without sequence homology to any known human gene and
siRNA directed against GAPDH served as negative controls. After
24 and 48h, RNA and protein were isolated to verify knockdown
efficiency.
Protein isolation and western blotting
Total protein extraction and western blotting were performed as
described (Sonvilla et al, 2008) using the following antibodies:
FGFR3 (C-15) (#sc-123, recognises both FGFR3 splice variants;
Santa Cruz Biotechnology, Inc., CA, USA), phospho-S6 (#2215)
and S6 Ribosomal Protein 1:1000 (#2212, Cell Signalling, Boston,
MA, USA), phospho-externally regulated kinase (ERK)1/2 (sam-
pler kit: phospho-p44/42 MAP Kinase Thr202/Tyr204, Cell
Signalling), ERK1/2 1:5000 (#06-182, Upstate, Lake Placid, NY,
USA), caspase 3 1:1000 (H277, Santa Cruz Biotechnology, Inc.)
and b-actin 1:5000 (AC-15, SIGMA, Saint Louis, MO, USA).
Cell viability and cell proliferation assays
Cells were seeded at a density of 3 10
3 cells per well into 96-well
plates. For knockdown experiments, cells were transfected with
siRNA directed against FGFR3 after 24 and 48h, and viability was
determined after an additional 48h recovery period. For growth
stimulation with recombinant growth factors, cells were serum
starved for 24h and then stimulated with recombinant FGF18
(hFGF18-25, Strathmann Biotec, Bovenau, Germany) for 4 days.
Cell viability was determined by 30 (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay (EZ4U; Biomedica,
Vienna, Austria). For determination of DNA synthesis, cells were
incubated with
3H-thymidine (1mCiml
–1) for 1h, washed twice
with phosphate-buffered saline and processed for scintillation
counting.
Colony formation assay
SW480 and HCT116 cells were plated at a density of 100 or 200
cells per well, respectively, onto six-well plates in medium
containing 10% FCS. After 10 days, the cells were washed with
phosphate-buffered saline and fixed with methanol for 20min.
After washing with phosphate-buffered saline, cells were stained
with 0.01% of crystal violet solution to assess colony formation.
Cell migration assay
Confluent monolayers of different cell lines were serum starved for
24h and ‘scratch’-wounded using a yellow pipette tip. At each time
point, four defined parts of each scratch were photographed and
individual scratch widths (mm, mean±s.d.) were measured using
MetaMorph software (Meta Imaging Series 6.1, Universal Imaging
Corporation, Dowingtown, PA, USA). Migration distance was
calculated from the difference of the scratch width.
For SW480 cells transfected with siRNA, as well as SW480 and
Caco2 cells infected with adenoviral constructs expressing
dominant-negative FGFRs, migration assays were performed using
8-mm-pore-sized PET track-etched membrane (BD-Falcon, Frank-
lin Lakes, NJ, USA) in 24-well plates. Cells were seeded at a density
of 0.5 10
5 cellscm
–2. After a migration period of 24 and 48h for
SW480 and Caco2 cells, respectively, the nitrocellulose filters were
removed and cells at the bottom of the membrane and in the lower
chamber were fixed and stained with crystal violet. The number of
cells or colonies was counted microscopically.
Tumour growth
SW480 cells were infected with 1 multiplicity of infection KD3-
IIIcv or GFPv on cell culture plates. After 24h, cells were harvested,
washed with phosphate-buffered saline and suspended in Ringer’s
solution. In all, 1 10
6 cells in 50ml Ringer’s solution were
subcutaneously injected into the rear flanks of immunodeficient
SCID/Balb/c recipient mice (female, aged 4 weeks, Harlan
Winkelmann, Borchen, Germany). Tumour formation was mon-
itored periodically by palpation, and tumour size was determined
using a vernier caliper. Tumour volume was calculated using the
formula (smaller diameter
2 larger diameter)/2. All experiments
were performed in triplicate and carried out according to the
Austrian and FELASA guidelines for animal care and protection.
Tissue sections of experimental tumours were analysed using
immunohistochemistry as previously described (Berger et al,
2005). Proliferation and apoptosis were evaluated by counting
Ki67-positive cells and apoptotic structures, respectively, from 3 to
5 random areas of each tumour section and calculated as a
percentage of total cells.
Cell death detection and caspase activity
Cell death was determined by staining for 30min with 5mgml
–1
Hoechst 33258 and 2mgml
–1propidium iodide 5 days after siRNA
transfection or adenoviral transduction. Alternatively, for deter-
mination of caspase activity, the medium was replaced by 50ml
rhodamine-labelled caspase substrate D2R (Alexis Biochemicals,
Lausen, CH, USA) and cells were incubated for 30min at 371C. The
fluorescent rhodamine cleavage product is released into the culture
supernatant and measured in the fluorescein isothiocyanate
channel at lex488/lem550nm on a fluorometer (Synergy HT,
Multi-Detection Microplate Reader, BIO-TEK Instruments, Inc.,
Winooski, VT, USA).
Statistical analysis
Tissue expression data were analysed by analysis of variance after
obtaining a Gaussian distribution by transforming to log values.
The relationship between tumour stage and shift in the FGFR3 IIIc/
IIIb ratio was determined in comparison with stage I using
contingency tables and Fisher’s exact test. All cell biological
results were analysed by Student’s t-test or Kruskal–Wallis test,
depending on the results of normality testing.
RESULTS
Expression of FGFR3 in colon carcinoma tumour tissues
Total RNA was isolated from normal and tumour-derived tissues
(N¼22) and expression of FGFR3 mRNA was measured by
quantitative real-time RT–PCR relative to GAPDH. Expression of
total FGFR3 mRNA was found to be downregulated in 20 of 22
tumour specimens, resulting in a significant overall reduction in
tumours compared with non-malignant colon tissue specimens
(Figure 1A, P¼0.0015). Expression of FGFR3 isoforms IIIb and
IIIc was determined for a larger number of tumour specimens
(n¼57) using isoform-specific real-time RT–PCR assays. The
FGFR3-IIIb was downregulated in 49 of these specimens. Expres-
sion of FGFR3-IIIb was downregulated with increasing stage
(Figure 1B; P¼0.0125, slope¼  1.9). By contrast, FGFR3-IIIc
expression increased with stage (Figure 1C; P¼0.0303, slope¼
þ0.84). As a consequence, the IIIb/IIIc ratio, compared with
normal mucosa, increased with stage at a slope of þ2.622
(P¼0.0023). The fraction of tumours with a higher IIIc/IIIb ratio
also significantly increased with higher stages (Table 1).
Colorectal carcinoma cell lines also expressed the IIIb and IIIc
variants of FGFR3 at different ratios, clearly showing FGFR3-IIIc
expression in the epithelial cell compartment. No FGFR3-IIIc was
detected in the adenoma cell lines, whereas the highest IIIc/IIIb
ratio was found in the H64 brain metastasis-derived cells
(Figure 1D).
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sImpact of FGFR3-IIIc on cell growth and clonogenicity
SW480 and HCT116 cells were used to create cell line models
stably overexpressing FGFR3. From the slowly growing Caco2 cells,
stable transfectants could not be obtained. Plasmids expressing
either wild-type FGFR3-IIIb or -IIIc receptors (WT3b and WT3c)
or kinase-dead dominant-negative mutants of both FGFR3-IIIb
and FGFR3-IIIc (KD3b and KD3c) were introduced by electro-
poration and stable transfectants were selected. Overexpression of
FGFR3 in pools of stable clones was checked by RT–PCR using
IIIb- or IIIc-specific primers on mRNA and with western blot
analysis on protein level. In IIIc transfectants, the receptor subtype
was found to be 15- to 20-fold at the RNA level, whereas expression
of the IIIb variant was not affected. In IIIb transfectants,
overexpression was 4100-fold for IIIb at the RNA level. A distinct
increase in total FGFR3 protein was found in all transfectants
(for details see Supplementary Material). Transient expression of
dominant-negative FGFR3 was achieved from an adenoviral
construct expressing KD3 (KD3-IIIcv). A GFP-tagged virus (GFPv),
an untagged Cv and uninfected parental SW480 cells were used for
comparison. Splice-variant IIIc mRNA was specifically over-
expressed up to 20-fold (Supplementary Material).
To determine the impact of the different FGFR3 constructs on
cell growth, stable SW480 transfectants were seeded at equal
density and kept in medium containing 10% FCS for up to 6 days.
Cell viability was determined at the indicated time points. Cells
expressing WT3c grew faster than control transfectants, reaching
similar density after 6 days. Growth of WT3b cells was also
increased, compared with control transfectants, but the effect was
smaller than for WT3c and only just significant. KD3b did not
affect cell growth in SW480 cells, but KD3c cultures showed
decreased growth at all time points (Figure 2A, left panel). This
effect became more severe with time in culture and KD3c
transfectants lost viability after 3–4 passages. By contrast,
vigorously growing cultures, the growth characteristics of which
were identical to control transfectants, could be isolated from
SW480-KD3b transfectants. DNA synthesis was measured by
3H-thymidine incorporation assays 24h after plating. DNA
synthesis was stimulated by WT3c but not by WT3b. Inhibition
was observed in KD3c overexpressing cells, whereas KD3b again
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Figure 1 Expression of fibroblast growth factor receptor 3 (FGFR3) mRNA in colorectal cancer. RNA was isolated from surgical specimens of colorectal
tumours and adjacent normal mucosa and expression of FGFR3 was quantified by reverse transcriptase PCR (RT–PCR). Expression levels were calculated
relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), normalised relative to expression in normal mucosa. Repeated assays from each specimen
yielded cycle threshold (Ct)-values o0.5 cycles apart. (A) Total FGFR; (B) FGFR3-IIIb; and (C) FGFR3-IIIc. (B and C) Results are grouped by stage of disease
and each column shows the individual values with the mean of expression marked by a horizontal line. Differences between tumour and adjacent normal
mucosa were analysed by analysis of variance from the log values of expression. P-values and linear trend are given in the inserts. (D) The FGFR3 splice-
variant pattern expressed in colorectal tumour cell lines was quantified by real-time RT–PCR (right panel, mean±s.d. of three independent experiments).
Table 1 FGFR3 subtype expression and staging in colorectal tumour specimen
Stage
Total number
of specimen (n)
Specimen with increasing
IIIc/IIIb ratio
%o f
total
Different from
stage I (P-value)
I5 0 0
II 26 12 43 0.0684 (NS)
III 15 9 60 0.0298 (*)
IV 6 4 67 0.0455 (*)
Abbreviation: FGFR3¼fibroblast growth factor receptor 3; NS, not significant. In all, 52 tumour specimens were classified according to the shift in the IIIc/IIIb ratio in comparison
with the adjacent normal mucosa. Differences were assessed from contingency tables by Fisher’s exact test.
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shad no impact (Figure 2A, right panel). Stable HCT116 transfec-
tants overexpressing FGFR3-IIIc were less sensitive to the impact
of FGFR3-IIIc overexpression and was inhibited by FGFR3-IIIb
overexpression (Figure 2B). Cell viability after 3 days in culture
was not affected by the WT3c or KD3b construct, but was
significantly decreased by WT3b and KD3c (70% of control).
3H-thymidine incorporation was stimulated by WT3c, reduced by
WT3b and KD3c, and not affected by KD3b (Figure 2B right
panel).
Differences in growth potential became even more obvious
under the stringent conditions of colony formation assays. SW480
cells were plated at 100 cells per well and colony formation was
determined after 10 days. Colony formation was increased about
two-fold in WT3c and almost completely suppressed in KD3c
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Figure 2 Impact of fibroblast growth factor receptor 3-IIIc (FGFR3-IIIc) on growth and clonogenicity. (A) SW480 and (B) HCT116 transfectants were
plated at 3 10
3 cells per well in 96-well plates and growth was determined by 30 (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay at
the indicated time points (A) or after 3 days (B). Data points represent the mean±s.e.m. of 10 determinations from two independent experiments (left
panels). In all, 2.5 10
4 cells were plated for assessment of DNA synthesis. After 24h, cultures were incubated with 1mCi ml
–1 3H-thymidine for 1h and
incorporation of radioactivity into DNA was determined as described in Sonvilla et al (2008) (right panels). (C) Stable SW480 and HCT116 transfectants
were plated at 100 and 200 cells per well, respectively, in six-well plates, fixed and stained with crystal violet 10 days later to show colony formation.
Colonies were counted from two experiments using duplicate cultures (means±s.e.m.). SW480 (left panel), HCT116 (right panel). (D) SW480 and Caco2
cells were infected with kinase-dead FGFR3 (KD3)-IIIcv or control virus (Cv). Cloning efficiency was determined from 200 cells per well and compared with
untransduced control (UC). *, **, *** and #, ### indicate increase or a decrease, respectively, as compared with vector controls at Po0.05, Po0.01 or
Po0.0001 (Student’s t-test). d, day.
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stransfectants. By contrast, KD3b increased plating of SW480 cells
(Figure 2C, left panel). Colony formation of HCT116 cells was also
enhanced by overexpression of WT3c, but the cells were less
sensitive to inhibition by KD3c. KD3b caused a decrease in plating
(Figure 2C, right panel). Impact of the dominant-negative
construct was also assessed by transduction with an adenoviral
vector in SW480 and Caco2 cells. Cv was used as control and
stimulated the clonogenicity of SW480 but not of Caco2 cells,
compared with uninfected cells (UC). KD3-IIIc virus severely
inhibited attachment in both cell lines (Figure 2D).
Induction of apoptosis by blocking FGFR3-IIIc signalling
The impact of KD3-IIIcv transduction on cell survival was assessed
and compared with Cv in SW480 (Figure 3; upper panels) and
Caco2 cells (Figure 3; lower panels). Multiplicity of infections of 1
and 20 were used for transduction of SW480 and Caco2 cells,
respectively. After 6 days, KD3-IIIcv reduced cell viability in both
cell lines (Figure 3A). In SW480 cell cultures, a 17% cell loss was
observed and the incidence of apoptotic cells was doubled. In
Caco2 cultures, a similar cell loss (14%) was accompanied by an
increase of only 15% in the incidence of apoptosis (Figure 3B).
Although this effect was relatively minor, it was also highly
reproducible and significant at Po0.01. In addition, protein lysates
were obtained on day 6 and procaspase 3 was analysed by western
blotting (Figure 3C). The amount of procaspase was decreased in
the KD3-IIIcv groups of both cell lines, indicating cleavage to
produce active caspase 3 (Figure 3C). Accordingly, caspase activity
increased in parallel (Figure 3D).
In addition, FGFR3-IIIc expression in SW480 cells was knocked
down using siRNA that caused a reduction of both mRNA and
protein levels (Figure 4A). The siRNA was most effective after
double transfection 24 and 48h after plating, reducing FGFR3-IIIc
mRNA by 75%, but only minimally affecting FGFR3-IIIb
(Figure 4A, left panel). The protein level was similarly reduced
by 30 and 50%, respectively (Figure 4A, right panel). Cell viability
was assessed another 48h later and found to be reduced by 35% as
compared with the scrambled control (Figure 4B). At the same
time, incidence of apoptosis was increased 4.7- and 2.7-fold,
respectively (Figure 4C).
3H-thymidine incorporation was inhib-
ited at all cell densities, but was strongest in dense cultures
(Figure 4D; 80 and 65% of control). To control for the subtype
specificity of the effects, a similar series of knockdown experi-
ments was performed for FGFR3-IIIb: siFGFR3-IIIb-1 caused a
90% reduction of FGFR3-IIIb mRNA and a 70% reduction of
FGFR3 protein, but no alteration of FGFR3-IIIc expression.
Knockdown of siFGFR3-IIIb2 was unreliable and was therefore
not included in the growth assays (Figure 5A). Downmodulation of
FGFR3-IIIb did not result in either a reduction of viable cells in the
culture or in a decrease of DNA synthesis (Figure 5B).
Impact of FGFR3-IIIc blockade on tumour growth in vivo
As in vitro growth assays strongly indicated an anti-tumourigenic
effect of FGFR3 blockade, tumour growth was assessed in vivo by
injection of KD3-IIIcv- and GFPv-transduced SW480 cells into
SCID mice. Tumour growth was significantly retarded by FGFR3
blockade as compared with GFPv-infected controls (Figure 6A)
and uninfected cells (data not shown). Tumour tissues were
analysed by staining paraffin-embedded sections with either
haematoxylin–eosin (Figure 6C) or antibodies recognising Ki67
(Figure 6D). Because of their larger size, GFP tumours contained
significantly larger areas of necrotic tissue. Analysis of growth
parameters was therefore restricted to non-necrotic tumour
regions. In these viable tumour areas, the fraction of Ki67-positive
cells was significantly decreased in KD3-IIIc tumours (Figure 6B,
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Figure 3 Induction of apoptosis by dominant-negative fibroblast growth factor receptor 3 (FGFR3). SW480 (upper panels) and Caco2 (lower panels)
cells were infected with adenoviral constructs expressing kinase-dead FGFR3-IIIc (KD3-IIIcv) and control virus (Cv) at multiplicity of infections (MOIs) of 1
(SW480) or 20 (Caco2). (A) Cell viability was determined 6 days later by 30 (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay. The
data points represent the mean±s.e.m. of two independent experiments using quadruplet cultures. (B) Apoptotic cells were detected after staining with
Hoechst dye and propidium iodide to visualise nuclear morphology and counted from 1000 cells, each in triplicate cultures. (C) To determine caspase
activation, cell lysates were analysed by western blot using a monoclonal antibody recognising procaspase 3. Inserts depict representative blots.
Quantification of band intensities was performed from three independent experiments. (D) Caspase activity was determined using a substrate
predominantly cleaved by caspase 3. The data points represent the mean±s.e.m. of two independent experiments using quadruplet cultures. *, **Indicate
increase as compared with Cv at Po0.05 and Po0.01, respectively. #, ## indicate decrease as compared with Cv at Po0.05 and Po0.01 (Student’s t-test).
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sleft panel), although incidence of apoptosis was increased
(Figure 6B, right panel), compared with control tumours.
Transduction of ligand-dependent signals
Previous experiments had shown that exogenous FGF18 did not
stimulate growth under standard conditions in FGFR3-low SW480
cells (Sonvilla et al, 2008). To determine whether FGFR3-IIIc can
confer FGF18 sensitivity to cells, receptor transfectants were kept
in serum-free culture medium for 2 days before stimulation with
recombinant FGF18 (Figure 7A). After 4 days , the cell number was
measured by MTT assay and demonstrated dose-dependent
growth stimulation in WT3c cells. KD3c cells were not stimulated
(Figure 7A, left panel). As the data suggest that FGFR3-IIIc confers
FGF18 responsiveness, the impact of FGFR3 inhibition on FGF18
sensitivity was determined by infecting cells with the dominant-
negative KD3-IIIcv and Cv before exposure to the growth factor.
This had no effect on FGF18-insenstitive SW480 cells (data not
shown). On the other hand, FGFR3-IIIc-high Caco2 cells
responded to FGF18 with a 25% increase in cell viability when
infected with control viruses, and KD3-IIIcv completely abolished
the response (Figure 7A, right panel).
To investigate the impact of FGFR3-IIIc on FGF18-dependent
downstream signalling, stable SW480-FGFR3 transfectants were
serum starved for 24h, stimulated with 10ngml
–1 recombinant
FGF18 and, 15min later, phosphorylation of ERK and S6 was
determined by western blotting. Phosphorylation of both signal-
ling molecules was stimulated by FGF18 only in WT3 cells to
132±0.3% for ERK and to 123±0.01% for S6. In KD3c cultures,
control levels of ERK phosphorylation were lower than in controls
or in WT3c transfectants, and the growth factor did not lead to
pathway stimulation (Figure 7B).
Impact of FGFR3-IIIc on cell migration
To assess whether FGFR3-IIIc mediates migration signals, we
performed migration assays with SW480 and Caco2 cells after
infection with dominant-negative KD3-IIIcv and Cv. Uninfected
cells and cells infected with Cv readily migrated through the filter,
but the dominant-negative FGFR construct KD3c significantly
reduced migration at comparable levels for both cell lines
(Figure 8A).
In addition, we performed scratch assays with stably FGFR3-
IIIc-transfected SW480 cells after 24h serum starvation. Migration
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sof cells was followed up for up to 40h (doubling time 448h). In
starvation medium without serum, all transfectants migrated 60–
100mm during the 40h period without any significant differences
between experimental groups (Figure 8B, left panel). Addition of
10ngml
–1 FGF18 stimulated WT3c cells to migrate 128mm
(P¼0.0005), whereas the pcDNA3 and KD3c groups remained
within the 60–100mm range (Figure 8B, center panel). A 10% FCS
stimulated migration in all three groups. pcDNA3 and WT3c
reached 274 and 246mm, respectively (Figure 8B, right panel; not
significantly different P¼0.052). KD3c inhibited migration as
compared with the pcDNA3 control (Figure 8B, right panel;
197mm, P¼0.01). However, KD3c cells were still stimulated by
10% serum (Figure 8B, left and right panels; P¼0.013).
DISCUSSION
The FGFR3 is a tyrosine kinase receptor, the constitutive activation
of which is involved in skeletal malformations (Bellus et al, 2000)
and drives tumour cell growth in bladder and cervix cancer
(Cappellen et al, 1999; Hernandez et al, 2006; Mhawech-Fauceglia
et al, 2006). Deregulation of FGFR3 signalling may be caused by
mutation, transcriptional regulation or differential splicing.
The latter mechanism most prominently affects the Ig-like loop
III, producing IIIb and IIIc variants, which are expressed
preferentially in epithelia and connective tissue, respectively
(Murgue et al, 1994). In colon carcinomas, receptor mutations
are rare (Jang et al, 2000), but aberrant splicing causes a decrease
in functional FGFR3-IIIb, accompanied by a switch to FGFR1-IIIc
(Jang, 2005).
Our results now confirm the downregulation of FGFR3-III, and
also demonstrate differential effects on the IIIb and IIIc variants.
Specifically, expression of the IIIc splice variant can be retained
better so that the IIIc/IIIb ratio is higher in tumour tissue than in
normal mucosa. This was observed in about 50% of the tumour
specimens analysed and preferentially in more advanced tumours.
The IIIc splice variant was also detected in colon carcinoma, but
not in adenoma-derived cell lines, demonstrating (1) that
expression of the splice variant is not only due to mesenchymal
contaminants but also comes from the epithelial compartment of
the tumour and (2) that it is upregulated during tumour
progression.
Switching of FGFR expression to the IIIc isotypes has been
shown for FGFR2 and FGFR1, and was described to be associated
with tumour progression in prostate (Yan et al, 1993; Carstens
et al, 1997; Feng et al, 1997) and bladder cancer (Chaffer et al,
2006). For FGFR3, mutation of the IIIc variant causes tumour
growth in multiple myeloma cells (Chesi et al, 2001). Our results
now demonstrate that overexpression of FGFR3-IIIc stimulates
tumour cell growth, whereas its blockade inhibits cell growth and
induced apoptosis in colorectal cancer cells. Overexpression or
blockade of FGFR3-IIIb had little impact on cell growth. Only in
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sHCT116-KD3b transfectants was colony formation also decreased
by blockade of IIIb; however, this effect was transient, and 3 or
more days after plating, no evidence of growth inhibition by the
construct remained. This is in agreement with the observation of
Jang (2005) that overexpression of WT3b in the human HCT116
colorectal carcinoma cell line has been shown to inhibit cloning
efficiency so that loss of expression in colorectal cancer per se
should enhance growth. Expression of the FGFR3-IIIc splice
variant as shown by our results is generally low, but seems to be
essential for the growth and migration of colorectal tumour cells.
In that manner, FGFR3-IIIc induced a distinctly different cellular
response than the IIIb variant, which may be due to its larger range
of ligands either by ligand-dependent heterodimerisation or
through ligand-dependent differences in receptor downregulation
and distribution to cellular compartments, as has also been
described for the epidermal growth factor receptor (Resat et al,
2003). Results from in vitro models indicate that the IIIc
splice variant is essential for the mediation of oncogenic FGF18
effects – such as colony formation, growth, survival and migration,
which was stimulated by expression of the WT3c allele in SW480
cells and, to a lesser extent, in HCT116 cells. SW480 cells also
acquired sensitivity to exogenous FGF18 after knockdown of
endogenous factor production (Shimokawa et al, 2003; Sonvilla
et al, 2008), suggesting that insensitivity was caused by autocrine
growth factor saturating the available receptors (Berger et al, 1999;
Barbieri et al, 2004; Reilly et al, 2004). Transfection of SW480 cells
with WT3c had the same effect, probably by providing additional
receptor binding sites. Transfectants responded by increased cell
viability, migration and activation of intracellular signalling
pathways. However, FGFR3-IIIc not only exclusively bind
FGF18, but also FGFs 1, 2, 4, 8 and 9, among which FGF9 is
expressed in colorectal tumour cells (data not shown). Similar to
FGF18, this FGF also stimulated cell growth when added to WT3c
transfectants, but did not affect controls, indicating another
possibility of autocrine growth stimulation (data not shown). An
oncogenic effect of FGFR3-IIIc is further supported by the
inhibition of colony formation and induction of apoptosis by
KD3c in all cell lines used and by the inhibition of FGF18 signals in
Caco2 cells.
Accumulating data suggest that FGFR3 is a therapeutic target in
both multiple myeloma and bladder cancer. Inhibition of this
receptor by either blocking antibody or small inhibitory molecules
was cytotoxic in multiple myeloma cells in vitro and in xenograft
models (Trudel et al, 2006; Xin et al, 2006). In bladder cancer cells,
knockdown of FGFR3 was achieved by short hairpin RNA
constructs, leading to decreased proliferation, reduced clonogeni-
city and soft agar growth (Tomlinson et al, 2007). Our results
confirm the strong anti-tumourigenic effect in vivo due to
disruption of FGFR3 signalling in colorectal cancer. Infection of
SW480 colon carcinoma cells with a KD3c-expressing adenovirus
reduced tumourigenicity in a SCID mouse model by about 40% by
both inhibition of proliferation and increased incidence of
apoptosis.
Using in vitro models, reduction of colony formation and
clonogenicity by KD3c could be shown. At higher cell densities, the
dominant-negative construct reduced viability and induced
apoptosis by activating caspase 3 by a non-mitochondrial pathway,
as indicated by a stable status of mitochondrial membrane
potential (data not shown). An additional effect of KD3c mutant
on other FGFRs by heterodimerisation cannot be ruled out at this
point. However, growth inhibition and induction of apoptosis
could also be achieved by FGFR3-IIIc but not by FGFR3-IIIb
knockdown, demonstrating that the IIIc splice variant is actually
crucial for malignant growth and survival. Even though the in vitro
effects may be relatively minor in some cases, together they are
believed to synergistically cooperate in the anti-tumourigenic
effect observed in vivo. As, for example, blocking of FGFR3
disrupts growth factor signalling and colony formation, both these
mechanisms may cooperate in inducing apoptosis by loss of
colony formation (Gilmore, 2005).
Assessment of FGFR-targeting strategies in tumour therapy has
to take into account its effect on cell migration, which constitutes
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Figure 8 Fibroblast growth factor receptor 3-IIIc (FGFR3-IIIc)-dependent tumour cell migration. (A) FGFR3-IIIc-dependent signalling was inhibited by
infection with dominant-negative adenoviral constructs in SW480 (left panel) and Caco2 cells (right panel). Cells were seeded into filter inserts at 0.5 10
5
cells per well and kept in 1% serum for 24h. Cell migration was determined by staining cells at the bottom of the membrane or in the lower chamber with
crystal violet. (B) Stable FGFR3 transfectants were grown to confluence in six-well plates and scratch wounded. Migration was determined by measuring
scratch closure over time. Data points represent the distance migrated by each culture. All data points are calculated as the mean±s.e.m. from four cultures,
with ** and # indicating an increase or decrease as compared with control at Po0.05 (Kruskal–Wallis test). NS, not significant.
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san important mechanism of invasion and metastasis (Dignass et al,
1994; Antoine et al, 2006). In neurons, FGFR1 associates with cell
adhesion molecules, most importantly N-CAM, to stimulate
neurite outgrowth and migration (Ronn et al, 2000). A similar
configuration has been observed between FGFR4, N-CAM and
N-cadherin in tumour cell migration (Cavallaro et al, 2001),
providing a mechanistic explanation of the impact FGFR4 has on
several tumour types (Stadler et al, 2006; Streit et al, 2006). Here,
we demonstrate for the first time a major impact of FGFR3 on the
migration of colon tumour cells. Although transfection of WT3c
conferred sensitivity to FGF18-induced tumour cell migration, the
dominant-negative KD3 virus reduced cell migration in both
SW480 and Caco2 cells, but still permitted migration induced by
10% FCS. Together, these results indicate that autocrine stimula-
tion by FGF18 is one, but not the only, mechanism inducing
tumour cell migration. This indicates involvement of migratory
signals unrelated to FGFRs, for example, c-met, which are also
common in colorectal cancer (Otte et al, 2000).
In summary, our data demonstrate that FGFR3-IIIc exerts
oncogenic effects in colorectal cancer cells by promoting in vitro
tumour cell growth, survival, migration and responsiveness to
oncogenic FGF ligands such as FGF18. Moreover, disruption of
FGFR3-IIIc signalling distinctly attenuated colorectal cancer xenograft
growth in SCID mice. This makes FGFR3-IIIc a promising candidate
target for therapeutic interventions in colorectal cancer.
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